Advertisement

Diabetes-Related Neuropathies

  • Christopher H. GibbonsEmail author
Chapter

Abstract

With an estimate of 350 million people in the world having diabetes by the year 2030, diabetes will be an enormous cause of neuropathy. Approximately 50% of those people developing diabetes will develop a clinically significant neuropathy. In addition, the increase in prediabetes prevalence, and the associated increase in neuropathy risk in that cohort, suggests an epidemic of neuropathy that is going to be a challenge for the healthcare system to handle. The majority of individuals with diabetic neuropathy have type 2 diabetes (~95%), although large numbers of individuals with prediabetes are at risk for any associated distal neuropathy as well. Typically individuals with type 1 diabetes do not develop neuropathy until at least 5 years after diagnosis, while those individuals with type 2 diabetes may have neuropathy at the time of diagnosis. Neuropathies can vary in clinical presentation from a distal symmetric neuropathy, mononeuropathy, cranial neuropathy, plexus neuropathy, or even autonomic neuropathy. In this chapter, the clinical presentation, diagnosis, and management of the various diabetes-related neuropathies are reviewed.

Keywords

Prediabetes Distal symmetric polyneuropathy Mixed distal symmetric polyneuropathy Distal symmetric small fiber neuropathy Cardiac autonomic neuropathy Autonomic neuropathy Diabetes Control and Complications Trial (DCCT) Treatment-induced neuropathy of diabetes Diabetic radiculoplexus neuropathy Mononeuropathy Cranial neuropathy Screening guideline American Diabetes Association 

References

  1. 1.
    Callaghan BC, Cheng H, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    CDC, National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011, CDC, Editor. 2011, Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar
  3. 3.
    DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes. 1988;37:476–81.CrossRefGoogle Scholar
  4. 4.
    Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  5. 5.
    Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10:276–82.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013;74:397–403.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40:136–54.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.PubMedCentralGoogle Scholar
  11. 11.
    Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5:397–405.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–11.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Cortez M, Singleton JR, Smith AG. Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol. 2014;126:109–22.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ. 2014;348:g1799.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Said G. Diabetic neuropathy – a review. Nat Clin Pract Neurol. 2007;3:331–40.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Clements RS Jr, Bell DS. Complications of diabetes. Prevalence, detection, current treatment, and prognosis. Am J Med. 1985;79:2–7.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol. 2008;21:527–33.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care. 2008;31(Suppl 2):S255–61.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–38.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract. 1991;13:63–7.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Callaghan B, McCammon R, Kerber K, Xu X, Langa KM, Feldman E. Tests and expenditures in the initial evaluation of peripheral neuropathy. Arch Intern Med. 2012;172:127–32.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Callaghan BC, Burke JF, Rodgers A, McCammon R, Langa KM, Feldman EL, et al. Expenditures in the elderly with peripheral neuropathy: where should we focus cost-control efforts? Neurol Clin Pract. 2013;3:421–30.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3–S14.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region. J Int Med Res. 2010;38:295–317.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.CrossRefGoogle Scholar
  27. 27.
    Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful diabetic neuropathy. Ther Adv Endocrinol Metab. 2011;2:27–38.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gibbons CH. Small fiber neuropathies. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1398–412.Google Scholar
  29. 29.
    Dyck PJ, Norell JE, Tritschler H, Schuette K, Samigullin R, Ziegler D, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care. 2007;30:2619–25.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Sommer C. Painful neuropathies. Curr Opin Neurol. 2003;16:623–8.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Zilliox LA, Ruby SK, Singh S, Zhan M, Russell JW. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complicat. 2015;29:372–7.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Low VA, Sandroni P, Fealey RD, Low PA. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve. 2006;34:57–61.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc. 1989;64:617–28.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Stewart JD. Sweating abnormalities and other autonomic disorders in diabetes mellitus. Mayo Clin Proc. 1989;64:712–5.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903–12, e44–9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili G, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst. 2010;15:202–7.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Boruchow SA, Gibbons CH. Utility of skin biopsy in management of small fiber neuropathy. Muscle Nerve. 2013;48:877–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Illigens BM, Gibbons CH. Sweat testing to evaluate autonomic function. Clin Auton Res. 2009;19(2):79–87.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Freeman R, Chase KP, Risk MR. Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy. Neurology. 2003;60:465–70.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. [Review] [45 refs]. J Clin Neurophysiol. 1994;11:568–83.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Dyck PJ, Zimmerman IR, Johnson DM, Gillen D, Hokanson JL, Karnes JL, et al. A standard test of heat-pain responses using CASE IV. J Neurol Sci. 1996;136:54–63.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Dyck PJ, Larson TS, O’Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care. 2000;23:510–7.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, et al. Natural progression of diabetic peripheral neuropathy in the zenarestat study population. Diabetes Care. 2004;27:1153–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care. 2009;32:1256–60.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O’Brien PC, et al. Autonomic Symptoms and Diabetic Neuropathy: a population-based study. Diabetes Care. 2004;27:2942–7.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160–73.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab. 2005;90:5896–903.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:334–9.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639–53.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–60.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Enck P, Frieling T. Pathophysiology of diabetic gastroparesis. Diabetes. 1997;46(Suppl 2):S77–81.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care. 1999;22:503–7.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Horvath VJ, Izbéki F, Lengyel C, Kempler P, Várkonyi T. Diabetic gastroparesis: functional/morphologic background, diagnosis, and treatment options. Curr Diab Rep. 2014;14:527.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Sellin JH, Chang EB. Therapy Insight: gastrointestinal complications of diabetes – pathophysiology and management. Nat Clin Pract Gastroenterol Hepatol. 2008;5:162–71.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5:17–39.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med. 2010;362:1628–30.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46–8.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology. 2015;85:1362–7.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Fedele D. Therapy Insight: sexual and bladder dysfunction associated with diabetes mellitus. Nat Clin Pract Urol. 2005;2:282–90.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Van Den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, et al. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care. 2009;32:664–70.CrossRefGoogle Scholar
  62. 62.
    Luo KR, Chao CC, Hsieh PC, Lue JH, Hsieh ST. Effect of glycemic control on sudomotor denervation in type 2 diabetes. Diabetes Care. 2012;35:612–6.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Low PA. Autonomic neuropathies. Curr Opin Neurol. 2002;15:605–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Cheshire WP, Freeman R. Disorders of sweating. Semin Neurol. 2003;23:399–406.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Lanting P, Bos JE, Aartsen J, Schuman L, Reichert-Thoen J, Heimans JJ. Assessment of pupillary light reflex latency and darkness adapted pupil size in control subjects and in diabetic patients with and without cardiovascular autonomic neuropathy. J Neurol Neurosurg Psychiatry. 1990;53:912–4.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Handb Clin Neurol. 2013;117:295–307.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Gibbons CH, Freeman R, Veves A. Diabetic neuropathy: a cross-sectional study of the relationships among tests of neurophysiology. Diabetes Care. 2010;33:2629–34.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Buijs RM, Swaab DF. Autonomic nervous system. In Handbook of clinical neurology, volume 117, 3rd series. Edinburgh: Elsevier; 2013.Google Scholar
  70. 70.
    Illigens BM, Gibbons CH. Sweat testing to evaluate autonomic function. Clin Auton Res. 2009;19:79–87.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Freeman R. Assessment of cardiovascular autonomic function. Clin Neurophysiol. 2006;117:716–30.CrossRefGoogle Scholar
  72. 72.
    Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Low PA, Benarroch EE. Clinical autonomic disorders. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. xii, 780 p., 16 p. of plates.Google Scholar
  74. 74.
    Freeman R. Autonomic peripheral neuropathy. Lancet. 2005;365:1259–70.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Freeman R. Autonomic peripheral neuropathy. Neurol Clin. 2007;25:277–301.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs. 2004;64:2667–88.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Caravati CM. Insulin neuritis: a case report. Va Med Monthly. 1933;59:745–6.Google Scholar
  78. 78.
    Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67:534–41.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138:43–52.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Gibbons CH. Treatment induced neuropathy of diabetes: an autonomic dysrecognition syndrome. Clin Auton Res. 2016;26:1.CrossRefGoogle Scholar
  81. 81.
    Group DR. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.CrossRefGoogle Scholar
  82. 82.
    Gibbons CH. Treatment induced neuropathy of diabetes-long term implications in type 1 diabetes. J Diabetes Complicat. 2017;31:715–20.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39:329–35.CrossRefGoogle Scholar
  84. 84.
    Sander HW, Chokroverty S. Diabetic amyotrophy: current concepts. [Review] [55 refs]. Semin Neurol. 1996;16:173–8.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25:477–91.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Callaghan BC, Price RS, Chen KS, Feldman EL. The importance of rare subtypes in diagnosis and treatment of peripheral neuropathy: a review. JAMA Neurol. 2015;72:1510–8.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Younger DS. Diabetic lumbosacral radiculoplexus neuropathy: a postmortem studied patient and review of the literature. J Neurol. 2011;258:1364–7.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Thaisetthawatkul P, Dyck PJ. Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol. 2010;12:95–9.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Llewelyn JG, Thomas PK, King RH. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol. 1998;245:159–65.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med. 2009;10:1476–80.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Tamburin S, Magrinelli F, Favaro F, Briani C, Zanette G. Long-term response of neuropathic pain to intravenous immunoglobulin in relapsing diabetic lumbosacral radiculoplexus neuropathy. A case report. Pain Pract. 2014;14:E85–90.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Fraser DM, Campbell IW, Ewing DJ, Clarke BF. Mononeuropathy in diabetes mellitus. Diabetes. 1979;28:96–101.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Albers JW, Brown MB, Sima AA, Greene DA. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group for Edit (Early Diabetes Intervention Trial). Muscle Nerve. 1996;19:140–6.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Hansson S. Segmental median nerve conduction measurements discriminate carpal tunnel syndrome from diabetic polyneuropathy. Muscle Nerve. 1995;18:445–53.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Vinik A, Mehrabyan A, Colen L, Boulton A. Focal entrapment neuropathies in diabetes. Diabetes Care. 2004;27:1783–8.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Malkoc M, Korkmaz Ö, Oltulu I, Seker A, Say F, Bulbul AM. Surgical treatment results of carpal tunnel syndrome in patients with and without type 2 diabetes mellitus. Srp Arh Celok Lek. 2014;142:675–9.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Gulabi D, Cecen G, Guclu B, Cecen A. Carpal tunnel release in patients with diabetes result in poorer outcome in long-term study. Eur J Orthop Surg Traumatol. 2014;24:1181–4.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Thomsen NO, Anderson GS, Björk J, Dahlin LB. Neurophysiological recovery 5 years after carpal tunnel release in patients with diabetes. Muscle Nerve. 2017;56:E59–64.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Cornblath DR, Vinik A, Feldman E, Freeman R, Boulton AJ. Surgical decompression for diabetic sensorimotor polyneuropathy. Diabetes Care. 2007;30:421–2.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Ross AT. Recurrent cranial nerve palsies in diabetes mellitus. Neurology. 1962;12:180–5.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Pecket P, Schattner A. Concurrent Bell’s palsy and diabetes mellitus: a diabetic mononeuropathy? J Neurol Neurosurg Psychiatry. 1982;45:652–5.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med. 2016;164:542–52.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Neurology, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations